Home » Newsletters » BioWorld

BioWorld

June 30, 1993

View Archived Issues

GREENWICH RAISES $11.8 MILLION IN STOCK SALE

CALBIOCHEM MOVES ACTIVITIES

LILLY TAKES OVER CENTORX

MASOPROCOL REVERSES MULTIPLE DRUG RESISTANCE

HOTH JOINS CELL GENESYS

IMMUNOGEN BEGINS TRIALS

BROAD PROCESS PATENT FOR 'FORCED EVOLUTION'

PROTEIN POLYMER GRANTS LICENSE TO CELLCO

RECIPE FOR IMPROVING ON NATURE

COLLABORATION TO RESEARCH OSTEOPOROSIS

ID BIOMED TEAMS WITH TM TECHNOLOGIES

HEMACARE REGISTRATION DECLARED EFFECTIVE

TRANSDERMAL GLUCOSE MONITORING PATENT ALLOWED

CELLEX DISTRIBUTION PACT WITH TOSOH

BTG'S GROWTH HORMONE LAUNCHED IN JAPAN

BRITISH BIO RESTRUCTURES RELATIONSHIP WITH TECHNE

RAC APPROVES AIS GENE THERAPY PROTOCOL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...